Amphastar Pharmaceuticals, Inc. (AMPH)
| Market Cap | 936.26M -34.0% |
| Revenue (ttm) | 730.02M +1.0% |
| Net Income | 78.55M -41.7% |
| EPS | 1.69 -37.0% |
| Shares Out | 42.54M |
| PE Ratio | 13.05 |
| Forward PE | 6.92 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 224,526 |
| Open | 21.88 |
| Previous Close | 21.88 |
| Day's Range | 21.69 - 22.15 |
| 52-Week Range | 16.65 - 31.26 |
| Beta | 0.90 |
| Analysts | Hold |
| Price Target | 22.50 (+2.23%) |
| Earnings Date | Aug 6, 2026 |
About AMPH
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the preven... [Read more]
Financial Performance
In 2025, Amphastar Pharmaceuticals's revenue was $719.89 million, a decrease of -1.65% compared to the previous year's $731.97 million. Earnings were $98.09 million, a decrease of -38.51%.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for AMPH stock is "Hold." The 12-month stock price target is $22.5, which is an increase of 2.23% from the latest price.
News
Amphastar price target raised to $23 from $20 at Barclays
Barclays raised the firm’s price target on Amphastar (AMPH) to $23 from $20 and keeps an Equal Weight rating on the shares.
Amphastar price target raised to $20 from $19 at Wells Fargo
Wells Fargo analyst Benjamin Burnett raised the firm’s price target on Amphastar (AMPH) to $20 from $19 and keeps an Equal Weight rating on the shares. The Baqsimi bounce back…
Amphastar Pharmaceuticals Earnings Call Transcript: Q2 2026
Revenue grew 5% year-over-year to $183.9 million, with improved gross margin and strong cash flow. Key brands showed resilient demand despite pricing and competitive pressures, while new product launches and pipeline progress supported growth. IMS facility remediation and BAQSIMI pricing issues are being actively managed.
Amphastar Pharmaceuticals Earnings release: Q2 2026
Amphastar Pharmaceuticals released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Amphastar Pharmaceuticals Slides: Q2 2026
Amphastar Pharmaceuticals has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.
Amphastar Pharmaceuticals Quarterly report: Q2 2026
Amphastar Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 6, 2026.
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026
Net revenues of $183.9 million for the three months ended June 30, 2026 GAAP net income of $30.3 million, or $0.67 per share, for the second quarter Adjusted non-GAAP net income of $40.8 million, or $...
Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 6, 2026
RANCHO CUCAMONGA, Calif., July 29, 2026 /PRNewswire/ -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that the Company will release results for its second quarter of 2026 ended June 3...
Trump's generic drug tariffs: What they could mean for medicine prices, manufacturers and supply
Trump plans tariffs of up to 200% on imported generic drugs after a two-year grace period aimed at encouraging U.S. manufacturing. But thin profit margins make tariffs harder to absorb than for brande...
Amphastar downgraded to Underperform from Neutral at BofA
BofA analyst Jason Gerberry downgraded Amphastar (AMPH) to Underperform from Neutral with a price target of $20, down from $25. The firm, which lowered estimates on a more modest outlook…
Amphastar Pharmaceuticals Transcript: 16th Annual East Coast IDEAS Conference
The company is shifting its pipeline toward proprietary and biosimilar drugs, investing heavily in R&D, and launching new products in large markets. Revenue is growing and the capital structure supports continued development, with key launches and milestones expected next year.
Amphastar Pharmaceuticals, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, June 08, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) or certain of its executive officers violated federal securiti...
Amphastar Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026
Expansion into proprietary and biosimilar products is underway, with generic Atrovent driving near-term revenue growth and exclusivity supporting strong margins. BAQSIMI faces pricing headwinds but mitigation is expected by Q3, while the pipeline targets a 2027 biosimilar launch and new preclinical assets.
Amphastar Pharmaceuticals Slides: FY 2026
Amphastar Pharmaceuticals has posted slides in relation to its FY 2026 quarterly earnings report, which was published on June 3, 2026.
Amphastar price target lowered to $20 from $23 at Barclays
Barclays lowered the firm’s price target on Amphastar (AMPH) to $20 from $23 and keeps an Equal Weight rating on the shares. The firm updated models in the specialty pharmaceutical…
Amphastar Pharmaceuticals Transcript: AGM 2026
The meeting covered director elections, auditor ratification, and executive compensation votes, with all proposals approved. No stockholder questions were submitted, and risks related to forward-looking statements were noted.
Amphastar Pharmaceuticals to Present at the 2026 Jefferies Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESS Newswire / May 27, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration, wil...
Amphastar downgraded to Equal Weight from Overweight at Wells Fargo
Wells Fargo analyst Benjamin Burnett downgraded Amphastar (AMPH) to Equal Weight from Overweight with a price target of $19, down from $30. The firm says the company’s revenue in 2026…
Amphastar Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2026
BAQSIMI sales were impacted by 340B double discounting, but mitigation steps and a price increase are expected to restore growth within a few quarters. Exiting unprofitable international markets and new product launches should improve margins, while pipeline expansion and accelerated share buybacks reflect a balanced growth and capital strategy.
Amphastar Pharmaceuticals Slides: FY 2026
Amphastar Pharmaceuticals has posted slides in relation to its FY 2026 quarterly earnings report, which was published on May 13, 2026.
Amphastar price target lowered to $21 from $25 at Piper Sandler
Piper Sandler lowered the firm’s price target on Amphastar (AMPH) to $21 from $25 and keeps a Neutral rating on the shares following quarterly results. The firm says that though…
Amphastar downgraded to Hold from Buy at Needham
Needham downgraded Amphastar (AMPH) to Hold from Buy.
Amphastar cut to Hold at Needham after ‘disappointing’ results
As previously reported, Needham downgraded Amphastar (AMPH) to Hold from Buy. The company reported top and bottom line misses for the second quarter in a row, with weakness coming from…
Amphastar Pharmaceuticals Earnings Call Transcript: Q1 2026
Q1 2026 revenue grew to $171.2M, driven by new launches and stable base business, though net income and margins declined due to pricing and product mix. BAQSIMI and Primatene MIST showed strong demand, while AMP-007's launch is expected to drive growth.
Amphastar Pharmaceuticals Earnings release: Q1 2026
Amphastar Pharmaceuticals released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.